At PBE2018 Massimo Maffei will give a talk on: «Production of high value natural plant products:
from the laboratory bench to the drugstore shelf»
«Production of high value natural plant products:
from the laboratory bench to the drugstore shelf»
Clinical research brings the latest therapies and pharmaceuticals
from the laboratory bench to the bedsides of real patients.
The new shop «is going to help the people who work here move ideas
from the laboratory bench to the patient faster and better,» says John Gallin, director of the Clinical Center.
Not exact matches
NIH backing for career training will have to not only inspire institutions to commit serious resources but also persuade potentially reluctant PIs to allow or even encourage postdocs to take time away
from the
bench for activities contributing to their own, rather than the lab's, advancement.If successful, however, this initiative could also focus PIs» attention on the fact that preparing postdocs for careers — and not having them merely provide cheap labor for research projects — is the most important reason for their presence in the nation's
laboratories.
«It's very challenging to go
from something that works on the
bench to something that works on a large - scale,» comments David E. Chavez, a chemist at Los Alamos National
Laboratory who was not involved in the research.
iBET's infrastructure comprises 16
laboratories fully equipped with state - of - the - art technology (70 m2 each), including a BSL2
laboratory for working with viruses; a GMP Analytical Services Unit certified by the INFARMED (the Portuguese medicines authority, EMA Portuguese branch) and by DGAV (the Portuguese veterinary authority) for quality control and batch release of human and veterinary pharmaceuticals, biopharmaceuticals as well as experimental new drugs; a GMP Mass - Spectroscopy Unit that provides state - of - the - art MS services to the scientific community and Industry; a 2600 m2 bio-pilot plant supporting production and purification of proteins ATMPs and vaccines
from bench top to 300 L scale and privileged access to GeniBET Biopharmaceuticals, an iBET spin - off producing ATMPs under cGMP certification for phase I / II / III clinical trials.
«By studying these diseases
from both the
laboratory bench and the perspective of patients with whom I have been fortunate to interact, I have developed a growing interest in the intersection of genetics and healthcare policy,» Dr. Wagner said.